Editor's Note: Green and red arrows refer to intraday stock price movement.NEW YORK ( TheStreet) -- CHANGE IN RATINGS AK Steel ( AKS) downgraded at Goldman from Neutral to Sell. Electrical steel market remains weak. Alexion Pharmaceuticals ( ALXN) downgraded at UBS from Buy to Neutral. $85 price target. New analyst believes that investors should wait for a better entry point. American Tower ( AMT) rated new Outperform at Cowen. 4G deployment will sustain strong revenue growth. Anadarko Petroleum ( APC) downgraded at Wells from Outperform to Market Perform, Wells Fargo said. Valuation call. Aeropostale ( ARO) downgraded at Wells. ARO was downgraded from Market Perform to Underperform, Wells Fargo said. Business trends have been slowing for a couple of quarters. Atmel ( ATML) rated new Outperform at Wedbush. Coverage of ATML was started with an Outperform rating. $18.50 price target. Company is logging new design wins. Booz Allen Hamilton ( BAH) initiated at Credit Suisse with a Neutral rating and $21 price target. Valuation is cheap, and earnings should outpace peers, Credit Suisse said. BAH is government services new growth stock. Baker Hughes ( BHI) upgraded at Goldman from Neutral to Buy. International margins should improve over the coming quarters. CH Robinson ( CHRW) rated new Hold at Jefferies. $86 price target. Stock is already factoring in improving business trends. Commercial Metals ( CMC) upgraded at Goldman from Sell to Neutral. Commercial construction demand should rise. CME Group ( CME) downgraded at Deutsche from Buy to Hold. $320 price target. Valuation call, as the stock gained 20% in the fourth quarter alone. Cognizant Technology Solutions ( CTSH) downgraded at Barclays to Equal Weight from Overweight as strong growth outlook is already priced-in, Barclays said. Price target increased to $77 from $72. Diamond Offshore ( DO) upgraded at Goldman from Sell to Buy, Goldman Sachs said. Company was also added to the Conviction Buy list, as the company has strong cyclical earnings power. Express Scripts ( ESRX) downgraded at FBR from Outperform to Market Perform, FBR Capital Markets said. Valuation call, based on a $57 price target. Fiserv ( FISV) upgraded at Oppenheimer from Perform to Outperform. $72 price target. Accelerating organic growth can drive margin expansion. Foot Locker ( FL) upgraded at Morgan Stanley from Underweight to Equal-weight, Morgan Stanley said. Footwear market still has pricing power.
Frontier Communications ( FTR) upgraded at Wells from Market Perform to Outperform, Wells Fargo said. Stock sports an attractive dividend yield and has multiple potential catalysts. Granite Construction ( GVA) downgraded at Morgan Stanley from Equal-weight to Underweight, Morgan Stanley said. Valuation call, as the stock has bounced 25% since September. $25 price target. JC Penney ( JCP) downgraded at Morgan Stanley from Equal-weight to Underweight, Morgan Stanley said. $25 price target. Shoppers are becoming more price sensitive, which could lead to increased markdowns. Nordstrom ( JWN) upgraded at Morgan Stanley from Equal-weight to Overweight, Morgan Stanley said. $46 price target. Luxury retail has better pricing power. Kohl's ( KSS) downgraded at Morgan Stanley from Overweight to Equal-weight, Morgan Stanley said. Expect higher markdowns across retail this year. Marathon Oil ( MRO) upgraded at Goldman to Buy, Goldman Sachs said. Company stands to benefit from improving refining margins. SRA International ( SRX) downgraded at Cowen from Outperform to Neutral, Cowen said. Valuation call, as the company lacks near-term catalysts. Syntel ( SYNT) upgraded at Wells from Market Perform to Outperform, Wells Fargo said. Channel checks suggest that consensus estimates could prove conservative. Syntel ( SYNT) upgraded at Deutsche from Hold to Buy, Deutsche Bank said. $57 price target. Company will likely post strong quarterly results and is carrying a lot of momentum into 2011. Tidewater ( TDW) upgraded at Credit Suisse to Outperform from Neutral. Turnaround in earnings is likely seeing as industry is in early stages of a replacement cycle, Credit Suisse said. Price target raised to $65 from $45. Pharmasset ( VRUS) downgraded at ThinkEquity from Buy to Hold, ThinkEquity said. $45 price target. Valuation call, as the stock is up more than 300% over the past two years.